Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data

JAMA Oncol. 2023 Jun 1;9(6):758-760. doi: 10.1001/jamaoncol.2023.0251.

Authors

Charu Aggarwal^{1

2}, Howard Jack West^{3

4}

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia.
³ Department of Medical Oncology, City of Hope Cancer Center, Duarte, California.
⁴ AccessHope, Los Angeles, California.

PMID: 37052928
DOI: 10.1001/jamaoncol.2023.0251

No abstract available

Plain language summary

This Viewpoint describes the use of broad molecular marker testing in patients with early-stage non–small cell lung cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Carcinoma, Non-Small-Cell Lung* / diagnosis
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / diagnosis
Lung Neoplasms* / genetics

Substances

Biomarkers